Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.16Syngene International Ltd. presents a financially sound but mixed performance. The company's greatest strengths are its exceptional financial stability and low debt levels, which provide a strong foundation and minimize long-term risk. It is also highly capable of covering its interest and dividend payments. Profitability appears robust, showing an ability to effectively convert revenue into profit. However, a significant area of concern is its growth trajectory. While revenues have grown, profits have been shrinking, indicating potential pressure on margins or rising operational costs. The company's efficiency in using its large assets to generate sales is also an area of weakness. The future outlook depends on its ability to reverse the negative profit trend and improve the productivity of its assets, even as it continues to invest heavily in its operations.
Health Score : 7.16Syngene International Ltd. presents a financially sound but mixed performance. The company's greatest strengths are its exceptional financial stability and low debt levels, which provide a strong foundation and minimize long-term risk. It is also highly capable of covering its interest and dividend payments. Profitability appears robust, showing an ability to effectively convert revenue into profit. However, a significant area of concern is its growth trajectory. While revenues have grown, profits have been shrinking, indicating potential pressure on margins or rising operational costs. The company's efficiency in using its large assets to generate sales is also an area of weakness. The future outlook depends on its ability to reverse the negative profit trend and improve the productivity of its assets, even as it continues to invest heavily in its operations.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
53.25
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
51.15
P/B RATIO
3.35
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
4.33
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-243.58
EV/EBITDA RATIO
17.33
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹402.05 as on Sep 1, 2026.
Growth Score : 4.80The company's growth profile is a key area of concern. Despite a history of strong revenue expansion and continued growth in its asset base, its profitability is on a downward trend. Both operating profit and net income have been contracting, based on a weighted analysis of recent and projected data. This divergence between top-line sales growth and bottom-line profit growth signals potential issues with cost control, pricing power, or changing market dynamics that are negatively impacting its earnings.
Revenue Growth RateExcellentOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateAverageNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.23 | 22.62 | 9.27 | 4.39 | 2.66 |
| Operating Profit Growth Rate | 9.59 | 26.78 | 7.96 | 2.75 | -12.15 |
| Earnings Per Share (EPS) Growth | -2.37 | 17.11 | 9.68 | -2.84 | -36.25 |
| Asset Growth Rate | 13.95 | 4.8 | 5.51 | 10.47 | 3.81 |
| Net Income Growth Rate | -2.22 | 17.17 | 9.91 | -2.75 | -36.09 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Ipca Laboratories Ltd | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
| 11 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 12 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 13 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 14 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 15 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤29th Apr 26
Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
Quarterly Report⬤22nd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Syngene International Ltd is a leading integrated contract research, development, and manufacturing organization (CRDMO) based in India. It offers comprehensive scientific services across discovery, development, and manufacturing domains to global pharmaceutical, biotechnology, nutrition, animal health, and consumer goods companies. Syngene is known for its world-class scientific expertise and state-of-the-art infrastructure.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Syngene International Ltd's P/E ratio (TTM) is 53.25, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Syngene International Ltd's P/B ratio is 3.35, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Syngene International Ltd's P/S ratio is 4.33, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Syngene International Ltd's PEG ratio is -243.58.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Syngene International Ltd's EV/EBITDA ratio is 17.33.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Syngene International Ltd's ROE is 6.55%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Syngene International Ltd's ROA is 13.01%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Syngene International Ltd's ROCE is 10%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Syngene International Ltd's operating margin is 24.55%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Syngene International Ltd's net margin is 8.48%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Syngene International Ltd's current ratio is 1.28.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Syngene International Ltd's debt-to-equity ratio is 0.09.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Syngene International Ltd's interest coverage ratio is 9.39.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Syngene International Ltd's DPS is ₹1.26.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Syngene International Ltd's EPS is -36.25.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹402.05. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1993
Headquarters: Bengaluru, Karnataka
Core Offerings: Discovery Services, Development Services, Manufacturing Services, Custom Research & Manufacturing Services (CRAMS)
Stock Listing: NSE (SYNGENE), BSE (539268)
Promoter: Biocon Limited
Syngene International Ltd was founded in 1993 as a subsidiary of Biocon Limited, initially focusing on contract research services. Over the years, it expanded its capabilities to include discovery, development, and manufacturing services. The company went public with its Initial Public Offering (IPO) in 2015, listing on both NSE and BSE. Syngene has continuously invested in expanding its research and manufacturing facilities, establishing itself as a global CRDMO player.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Discovery Services | 32% | N/A (consolidated EBITDA margin reported) |
| Development Services | 29% | N/A (consolidated EBITDA margin reported) |
| Manufacturing Services | 39% | N/A (consolidated EBITDA margin reported) |
Discovery Services: Offers early-stage research capabilities including target identification and validation, lead generation and optimization, and in vivo/in vitro biology. This segment supports clients from concept to candidate selection.
Development Services: Provides comprehensive solutions for preclinical and clinical development, encompassing drug substance development, drug product development, analytical and bioanalytical services, and toxicology studies.
Manufacturing Services: Specializes in the manufacturing of small and large molecules, including active pharmaceutical ingredients (APIs) and drug products, adhering to global regulatory standards. This includes cGMP manufacturing for clinical and commercial supply.
Jonathan Hunt - Managing Director & CEO. Mr. Hunt has over 30 years of experience in the global pharmaceutical industry, holding senior leadership roles across R&D, commercial, and general management.
Syngene USA Inc.
AIT Therapeutics Private Limited
Syngene Europe SAS
No major recent corporate actions (like bonus or rights issues) on record. Regular small-scale M&A or acquisitions of capabilities occur as part of business growth.
The Syngene International Ltd share price today is ₹402.05 on NSE (SYNGENE), as of 26 Sept 2026.
As of 25 Sept 2026, Syngene International Ltd share price is ₹402.05, with previous close ₹402.05. Today's range is ₹402.05 to ₹402.05. The 52-week range is ₹360.40 to ₹678.95.
As of today, Syngene International Ltd's market cap is ₹16,202.61 crore (Mid Cap).
Syngene International Ltd's current P/E ratio is 53.25, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 36.
Syngene International Ltd's current P/B ratio is 3.35.
Syngene International Ltd's current dividend yield is 0.31%. Last dividend of ₹1.25 per share was declared on 21-Aug-2024 (expected payment post AGM for FY24 dividend).
Syngene International Ltd's EPS (TTM) is ₹-36.25.
Syngene International Ltd is a leading integrated contract research, development, and manufacturing organization (CRDMO) based in India. It offers comprehensive scientific services across discovery, development, and manufacturing domains to global pharmaceutical, biotechnology, nutrition, animal health, and consumer goods companies. Syngene is known for its world-class scientific expertise and state-of-the-art infrastructure.
Syngene International Ltd is promoted by Biocon Limited, holding 52.68% as of 25 Sept 2026.
Syngene International Ltd is listed on NSE (SYNGENE) and BSE (539268). Its next quarterly results are expected on July/August 2024 (Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)
